ASPIRE BIOPHARMA HOLDINGS, INC. (ASBP)

Every figure this model derived for ASBP, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
cash 12,167,136 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 13,465,544 AssetsCurrent 2026-06-30
current liabilities 1,686,196 LiabilitiesCurrent 2026-06-30
equity 11,757,821 StockholdersEquity 2026-06-30
interest expense 9,308,766 InterestExpenseNonoperating 2026-06-30
ocf -7,185,846 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 97,659 RevenueFromContractWithCustomerIncludingAssessedTax 2026-06-30
sbc 157,500 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up ASBP on one particular measure came for.

RatioValue
current ratio7.99
current ratio reported7.99
dilution pct116.8
interest cover-0.79
sbc pct revenue161.28

What to be careful about

What this model itself distrusts about ASBP's figures. Written by the derivation as it ran, not added afterwards.